预防性麦卢卡蜂蜜减少肺癌放化疗相关食管炎的随机2期试验:NRG Oncology RTOG 1012结果
该随机2期试验比较了液体蜂蜜、蜂蜜含片与标准支持治疗对肺癌放化疗所致放射性食管炎的预防效果。除液体蜂蜜组4周时阿片类药物使用显著少于支持治疗组(P=.03)外,其他次要终点均无差异。
要点
- 蜂蜜方案未优于最佳支持治疗预防放射性食管炎。
- 4周时吞咽疼痛评分变化各组间无显著差异。
- 液体蜂蜜组4周时阿片类药物使用显著少于支持治疗组(P=.03)。
核心结论
- 按本方案给予蜂蜜未能优于最佳支持治疗预防放射性食管炎。
- 需要进一步测试其他类型蜂蜜并研究其作用机制。
研究设计与样本
- 随机2期试验,患者按食管接受特定辐射剂量的百分比(V60 Gy食管<30%或≥30%)分层。
- 患者随机分为支持治疗组(53例)、液体麦卢卡蜂蜜组(54例)和蜂蜜含片组(56例)。
- 主要终点为4周时患者报告的吞咽疼痛(11点数字评定量表,NRPS)变化。
主要发现
- 4周时NRPS变化的主要终点在各组间无显著差异。
- 除液体蜂蜜组与支持治疗组在治疗4周时阿片类药物使用有显著差异(P=.03,支持治疗组更多患者使用阿片类药物)外,其他次要终点均无差异。
关键数值与推荐
- 主要终点为4周时NRPS评分变化,研究设计检测15%的相对降低。
- 分层因素为V60 Gy食管<30%或≥30%。
- 液体蜂蜜组与支持治疗组4周时阿片类药物使用差异显著(P=.03)。
临床怎么用
- 不推荐按本试验方案使用蜂蜜预防肺癌放化疗相关食管炎。
- 液体蜂蜜可能减少阿片类药物使用,但需进一步验证。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Randomized trials have shown that honey is effective for the prevention of radiation-induced mucositis in head and neck cancer patients. Because there is no efficacious preventative for radiation esophagitis in lung cancer patients, this trial compared liquid honey, honey lozenges, and standard supportive care for radiation esophagitis. METHODS: The patients were stratified by percentage of esophagus receiving specific radiation dose (V60 Gy esophagus <30% or ≥30%) and were then randomized between supportive care, 10 mL of liquid manuka honey 4 times a day, and 2 lozenges (10 mL of dehydrated manuka honey) 4 times a day during concurrent chemotherapy and radiation therapy. The primary endpoint was patient-reported pain on swallowing, with the use of an 11-point (0-10) scale at 4 weeks (Numerical Rating Pain Scale, NRPS). The study was designed to detect a 15% relative reduction of change in NRPS score. The secondary endpoints were trend of pain over time, opioid use, clinically graded and patient-reported adverse events, weight loss, dysphagia, nutritional status, and quality of life. RESULTS: 53 patients were randomized to supportive care, 54 were randomized to liquid honey, and 56 were randomized to lozenge honey. There was no significant difference in the primary endpoint of change in the NRPS at 4 weeks between arms. There were no differences in any of the secondary endpoints except for opioid use at 4 weeks during treatment between the supportive care and liquid honey arms, which was found to be significant (P=.03), with more patients on the supportive care arm taking opioids. CONCLUSION: Honey as prescribed within this protocol was not superior to best supportive care in preventing radiation esophagitis. Further testing of other types of honey and research into the mechanisms of action are needed.
引用
- Fogh SE, Deshmukh S, Berk LB, et al. A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012. Int J Radiat Oncol Biol Phys. 2016. PMID: 28244415. doi:10.1016/j.ijrobp.2016.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。